中国药业2016，Vol.25Issue(13)：46-48,3.
替莫唑胺用于恶性神经胶质瘤术后化学治疗35例及安全性评价
Temozolomide Used for Chemotherapy after Malignant Glioma Operation in 35 Cases and Its Safety Evaluation
梁鸿 1任明亮 1王旭辉 1徐伦山1
作者信息
- 1. 中国人民解放军第三军医大学大坪医院野战外科研究所神经外科，重庆 400042
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of temozolomide ( TMZ ) used for chemotherapy in the treatment of human ma-lignant gliomas. Methods 35 cases of postoperative pathologically confirmed malignant glioma patients from January 2013 to January 2016 were seleceted and given chemotherapy with TMZ. All cases were followed up to compare the clinical efficacy, quality of life scores during treatment, and the occurrence of adverse reactions. Results At the end of the full course of TMZ treatment, the overall response rate of the 35 cases was 57. 15% and disease control rate was 80. 01%. Pre-treatment quality of life score was ( 30. 67 ± 8. 03 ) points, which was significantly lower than that ( 83. 46 ± 11. 7 ) points after treatment; adverse reactions included 13 cases of anorexia, constipation and other gastrointestinal symptoms ( 37. 14%) , 4 cases of leukopenia ( 11. 43% ) , and 1 case of pseudo-progress ( 2. 86%) . Conclusion Treatment of malignant gliomas with TMZ has better clinical efficacy and less adverse reactions. It is well toler-ated and is an ideal drug for postoperative adjuvant chemotherapy for malignant glioma.关键词
替莫唑胺/恶性神经胶质瘤/疗效/安全性Key words
temozolomide/malignant gliomas/efficacy/safety分类
医药卫生引用本文复制引用
梁鸿,任明亮,王旭辉,徐伦山..替莫唑胺用于恶性神经胶质瘤术后化学治疗35例及安全性评价[J].中国药业,2016,25(13):46-48,3.
